Qiagen (NYSE:QGEN) Receives $48.42 Average Price Target from Analysts

Qiagen (NYSE:QGEN) has earned a consensus rating of “Hold” from the ten brokerages that are currently covering the company, Marketbeat reports. Seven equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 1 year target price among analysts that have covered the stock in the last year is $48.42.

QGEN has been the topic of a number of recent analyst reports. Baird R W cut shares of Qiagen from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, February 19th. Wall Street Zen raised shares of Qiagen from a “buy” rating to a “strong-buy” rating in a report on Thursday, May 15th. Robert W. Baird upped their target price on shares of Qiagen from $42.00 to $43.00 and gave the stock a “neutral” rating in a research report on Monday, April 21st. Finally, Redburn Atlantic downgraded shares of Qiagen from a “buy” rating to a “neutral” rating in a research report on Friday, April 4th.

Qiagen Price Performance

Shares of QGEN opened at $46.24 on Friday. The company has a current ratio of 3.61, a quick ratio of 3.09 and a debt-to-equity ratio of 0.38. The stock’s 50 day moving average is $42.50 and its two-hundred day moving average is $42.12. Qiagen has a twelve month low of $37.63 and a twelve month high of $49.30. The firm has a market capitalization of $10.28 billion, a PE ratio of 128.76, a P/E/G ratio of 2.39 and a beta of 0.67.

Qiagen (NYSE:QGEN) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $0.55 earnings per share for the quarter, beating analysts’ consensus estimates of $0.50 by $0.05. The firm had revenue of $483.46 million for the quarter, compared to the consensus estimate of $465.66 million. Qiagen had a return on equity of 13.92% and a net margin of 4.23%. The company’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same period in the previous year, the business earned $0.44 earnings per share. Research analysts anticipate that Qiagen will post 2.26 earnings per share for the current year.

Hedge Funds Weigh In On Qiagen

Several hedge funds have recently added to or reduced their stakes in the business. Groupama Asset Managment lifted its holdings in shares of Qiagen by 8,074.0% in the fourth quarter. Groupama Asset Managment now owns 31,817,740 shares of the company’s stock valued at $1,416,844,000 after purchasing an additional 32,216,761 shares in the last quarter. Massachusetts Financial Services Co. MA raised its position in shares of Qiagen by 9.5% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 25,319,332 shares of the company’s stock worth $1,127,470,000 after purchasing an additional 2,202,040 shares during the last quarter. Wellington Management Group LLP raised its position in shares of Qiagen by 12.2% during the 1st quarter. Wellington Management Group LLP now owns 24,438,441 shares of the company’s stock worth $972,191,000 after purchasing an additional 2,656,136 shares during the last quarter. Vanguard Group Inc. lifted its stake in Qiagen by 0.9% in the 4th quarter. Vanguard Group Inc. now owns 8,879,089 shares of the company’s stock valued at $397,937,000 after buying an additional 77,119 shares in the last quarter. Finally, Deutsche Bank AG grew its holdings in Qiagen by 57.5% during the 1st quarter. Deutsche Bank AG now owns 4,491,131 shares of the company’s stock valued at $180,319,000 after buying an additional 1,639,621 shares during the last quarter. 70.00% of the stock is currently owned by hedge funds and other institutional investors.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.